B
BetterLife Pharma Inc
CNSX:BETR
BetterLife Pharma Inc
CNSX:BETR
Price:
0.07
CAD
-6.67%
Market Closed
Market Cap:
CA$10.6m
Relative Value
There is not enough data to reliably calculate the relative value of BETR.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BETR
Relative Value
Base Case
Not Available
Multiples Across Competitors
BETR Competitors Multiples
BetterLife Pharma Inc Competitors
BetterLife Pharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
B
|
BetterLife Pharma Inc
CNSX:BETR
|
10.6m CAD | 0 | -5.7 | -5.5 | -5.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
866.9B USD | 13.3 | 42 | 28.4 | 30.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
250.6B CHF | 4.1 | 19.5 | 11.5 | 13 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP | 5 | 28.6 | 15.9 | 22.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.9B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
240.1B USD | 103.6 | -82.1 | 380.1 | 953.2 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.9B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117B USD | 2.4 | 16.6 | 7 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
